Holen Sie sich die Stockscreener-App
0.40
60.78%
-0.62
Handel nachbörslich:
.40
Schlusskurs vom Vortag:
$1.02
Offen:
$0.8801
24-Stunden-Volumen:
19.15M
Relative Volume:
39.86
Marktkapitalisierung:
$2.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.33M
KGV:
-0.0143
EPS:
-28.0369
Netto-Cashflow:
$-24.28M
1W Leistung:
-81.13%
1M Leistung:
-85.66%
6M Leistung:
-90.68%
1J Leistung:
-97.45%
1-Tages-Spanne:
$0.3123
$1.069
1-Wochen-Bereich:
$0.3123
$2.26
52-Wochen-Spanne:
$0.3123
$18.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.40 | 15.47M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
MBRX|Moleculin Biotech Inc|Price:2.190|Chg%:+0.070 - TradingKey
Moleculin Biotech Inc (MBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Moleculin Biotech, Inc. Revenue Breakdown – NASDAQ:MBRX - TradingView
TradingKey - TradingKey
Enterprise value to EBIT forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
MBRX|Moleculin Biotech Inc|Price:2.160|Chg%:-0.030 - TradingKey
Moleculin Biotech Inc (MBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moleculin Biotech Inc (MBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Moleculin Biotech Inc (MBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Moleculin Biotech Inc (MBRX) Institutional Confidence - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.150|Chg%:+0.030 - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.160|Chg%:+0.040 - TradingKey
Moleculin Biotech Inc (MBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Moleculin Biotech Inc (MBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MBRX stock trades around recent lows as Moleculin focuses on cash runway and clinical progress - Ad-hoc-news.de
MBRX stock holds the line as Moleculin advances its pipeline - Ad-hoc-news.de
MBRX Q1 2026 Earnings: Wider-Than-Expected Loss Reflects Continued R&D InvestmentHealthcare Earnings Report - dars.gov.et
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Enterprise value to revenue forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Price to sales forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Price to book forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Moleculin Biotech (MBRX) Weakens: Stock Drops 6.56% as Key Support Levels TestedTrend Reversal Picks - dars.gov.et
Enterprise value to EBITDA forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Price to earnings forward of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech focuses on oncology pipeline and Nasdaq listing - ad-hoc-news.de
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor 'What This Means' Segment - marketscreener.com
Moleculin CEO discusses preliminary results from leukemia trial By Investing.com - Investing.com Australia
Moleculin CEO discusses preliminary results from leukemia trial - Investing.com
Moleculin reports positive early results from P... - Pluang
Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment - Quiver Quantitative
Moleculin CEO, Walter Klemp, Highlights Positive - GlobeNewswire
Moleculin Biotech (MBRX) Shares Slide 9% as Stock Approaches Key Support LevelVolume Breakout Ideas - dars.gov.et
Moleculin Biotech | 8-K: Current report - Moomoo
MBRXMoleculin Biotech Inc Dividends - Finviz
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI
Why is Moleculin stock falling today? - MSN
Moleculin Biotech (MBRX) Plunges 25% as Key Support Nears—What’s Behind the Sharp DeclineATR Stop - dars.gov.et
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance - Asianet Newsable
Moleculin Biotech, Inc. Financial Disclosures & Filings - TradingView
Why is Moleculin Stock Falling Today? - Benzinga
H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Moleculin Biotech (MBRX) Reports Positive Efficacy Results in Ph - GuruFocus
Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data. - Bitget
Moleculin reports positive interim data from AML trial - Investing.com
Moleculin Biotech Updates Investors With New Presentation - TipRanks
Moleculin Biotech Reports Promising Annamycin AML Trial Data - TipRanks
Moleculin Biotech, Inc. Shares June 2026 Investor Presentation and Key Regulatory Updates - Minichart
Moleculin reports positive interim data from AML trial By Investing.com - Investing.com India
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control - The Manila Times
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):